Evaluation of the effects of Losartan in patients with corona virus disease 2019

Phase 3

Recruiting

• Conditions: Corona virus disease 2019 (COVID-19).; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20180802040678N4
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Laboratory (RT-PCR of oropharyngeal swab) confirmed COVID-19
Stable hemodynamic condition
Blood pressure =130/85 mmHg

Exclusion Criteria

Patient's critical condition
Cough exacerbation after initiating Losartan
Increasing blood potassium levels or high baseline potassium levels
New anemia
Shock or decreasing blood pressure = 90/60 mmHg after Losartan initiating
Angioedema
Acute hepatic failure
Acute renal failure
Bilateral renal artery stenosis
History of uncontrolled hypertension
Pregnancy and lactation
History of treatment with ACE inhibitors and ARB inhibitors
Treatment with phenobarbital, rifampin and fluconazole

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality. Timepoint: 28 days. Method of measurement: Number of death.;Performance of patients. Timepoint: Primary and 14 days after. Method of measurement: Sequential Organ Failure Assessment (SOFA) Respiratory Score.;Length of hospitalization. Timepoint: 28 days. Method of measurement: Days between admission to discharge.;Laboratory Findings. Timepoint: Primary and 14 days after. Method of measurement: Laboratory methods.